Norinchukin Bank’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.39M Sell
13,935
-197
-1% -$73.1K 0.05% 188
2026
Q1
$4.14M Sell
14,132
-131
-0.9% -$43.1K 0.05% 208
2025
Q4
$5M Buy
14,263
+829
+6% +$280K 0.06% 176
2025
Q3
$4.34M Sell
13,434
-148
-1% -$46K 0.06% 184
2025
Q2
$5.28M Buy
13,582
+1,036
+8% +$417K 0.08% 155
2025
Q1
$5.46M Buy
12,546
+1,721
+16% +$691K 0.1% 130
2024
Q4
$3.99M Buy
10,825
+1,063
+11% +$445K 0.08% 142
2024
Q3
$5.08M Buy
9,762
+1,456
+18% +$778K 0.12% 112
2024
Q2
$4.5M Buy
8,306
+67
+0.8% +$35.4K 0.13% 102
2024
Q1
$4.27M Sell
8,239
-131
-2% -$65.2K 0.13% 103
2023
Q4
$3.95M Sell
8,370
-979
-10% -$453K 0.09% 113
2023
Q3
$4.07M Sell
9,349
-12,054
-56% -$5.47M 0.1% 114
2023
Q2
$9.51M Buy
21,403
+5,740
+37% +$2.65M 0.16% 102
2023
Q1
$7.2M Buy
15,663
+464
+3% +$221K 0.14% 99
2022
Q4
$7.8M Sell
15,199
-3,897
-20% -$1.98M 0.17% 90
2022
Q3
$8.67M Buy
19,096
+2,205
+13% +$1.06M 0.18% 87
2022
Q2
$8.15M Sell
16,891
-5,706
-25% -$2.82M 0.16% 87
2022
Q1
$11.1M Buy
22,597
+1,773
+9% +$810K 0.15% 101
2021
Q4
$9.65M Sell
20,824
-228
-1% -$95.9K 0.12% 106
2021
Q3
$7.85M Buy
21,052
+780
+4% +$296K 0.11% 117
2021
Q2
$7.74M Sell
20,272
-98
-0.5% -$37.5K 0.11% 110
2021
Q1
$7.31M Buy
20,370
+16
+0.1% +$5.14K 0.1% 111
2020
Q4
$6.54M Sell
20,354
-746
-4% -$229K 0.09% 109
2020
Q3
$5.67M Buy
21,100
+195
+0.9% +$52.5K 0.09% 109
2020
Q2
$5.5M Sell
20,905
-314
-1% -$83.8K 0.09% 107
2020
Q1
$4.82M Sell
21,219
-12,355
-37% -$3.37M 0.09% 114
2019
Q4
$10.1M Sell
33,574
-3,496
-9% -$962K 0.13% 106
2019
Q3
$8.9M Buy
37,070
+835
+2% +$229K 0.13% 114
2019
Q2
$10.2M Sell
36,235
-12,564
-26% -$3.43M 0.16% 92
2019
Q1
$14M Buy
48,799
+1,418
+3% +$410K 0.18% 102
2018
Q4
$12.4M Buy
47,381
+13,947
+42% +$3.84M 0.17% 101
2018
Q3
$9.16M Buy
33,434
+4,520
+16% +$1.17M 0.12% 112
2018
Q2
$6.88M Buy
28,914
+5,483
+23% +$1.27M 0.1% 118
2018
Q1
$5.15M Buy
23,431
+2,902
+14% +$682K 0.09% 128
2017
Q4
$4.62M Buy
20,529
+983
+5% +$209K 0.08% 127
2017
Q3
$3.71M Buy
19,546
+1,157
+6% +$220K 0.07% 152
2017
Q2
$3.46M Buy
18,389
+1,210
+7% +$217K 0.07% 152
2017
Q1
$2.84M Buy
17,179
+1,198
+7% +$191K 0.06% 161
2016
Q4
$2.3M Buy
15,981
+1,891
+13% +$253K 0.05% 178
2016
Q3
$1.77M Buy
14,090
+298
+2% +$38.5K 0.04% 225
2016
Q2
$1.81M Sell
13,792
-9,609
-41% -$1.31M 0.04% 214
2016
Q1
$3.25M Sell
23,401
-17,584
-43% -$2.35M 0.08% 138
2015
Q4
$5.71M Sell
40,985
-1,276
-3% -$176K 0.15% 95
2015
Q3
$5.92M Buy
42,261
+17,076
+68% +$2.57M 0.15% 95
2015
Q2
$4.13M Sell
25,185
-833
-3% -$133K 0.11% 108
2015
Q1
$4.02M Buy
26,018
+1,840
+8% +$262K 0.1% 113
2014
Q4
$3.04M Buy
24,178
+11,223
+87% +$1.39M 0.07% 133
2014
Q3
$1.55M Buy
12,955
+2,519
+24% +$289K 0.04% 164
2014
Q2
$1.12M Sell
10,436
-1,252
-11% -$129K 0.03% 181
2014
Q1
$1.16M Buy
11,688
+653
+6% +$59.1K 0.03% 185
2013
Q4
$1.02M Sell
11,035
-194
-2% -$17.2K 0.03% 187
2013
Q3
$939K Buy
11,229
+826
+8% +$70.8K 0.03% 184
2013
Q2
$851K Buy
+10,403
New +$779K 0.03% 178

Other funds holding ELV

Norinchukin Bank's ELV Position: Q2 2026 in Review

Norinchukin Bank reduced its Elevance Health (ELV) stake by 1.4% in Q2 2026, selling an estimated $73.1K and leaving 13,935 shares worth $5.39M. The position accounts for 0.05% of the portfolio, ranked #188.

Norinchukin Bank first reported a position in ELV in Q2 2013 and has held it in 53 quarters since. The position peaked at $14M in Q1 2019. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Norinchukin Bank held 13,935 shares of Elevance Health worth $5.39M as of Q2 2026.
  • Norinchukin Bank sold 197 Elevance Health shares in Q2 2026, an estimated $73.1K.
  • Elevance Health made up 0.05% of Norinchukin Bank's portfolio in Q2 2026, its #188 holding.
  • Norinchukin Bank first reported a position in Elevance Health in Q2 2013 and has held it in 53 quarters since.
  • Norinchukin Bank's Elevance Health position peaked at $14M in Q1 2019.
  • 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Norinchukin Bank's 13F filing for Q2 2026, filed 14 Aug 2026.